Trials / Not Yet Recruiting

Not Yet RecruitingNCT07286331

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer

Status: Not Yet Recruiting
Phase: Phase 3
Study type: Interventional
Enrollment: 600 (estimated)

Sponsor: GlaxoSmithKline · Industry
Sex: Female
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This study specifically aims to evaluate how well GSK5733584 works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether GSK5733584 is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs

Conditions

Neoplasms, Endometrial

Interventions

Type	Name	Description
DRUG	GSK5733584	GSK5733584 will be administered
DRUG	Paclitaxel	Paclitaxel will be administered
DRUG	Doxorubicin	Doxorubicin will be administered

Timeline

Start date: 2026-06-09
Primary completion: 2028-02-29
Completion: 2029-05-30
First posted: 2025-12-16
Last updated: 2026-03-11

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT07286331. Inclusion in this directory is not an endorsement.